GTx Inc. is studying enobosarm (Ostarine, GTx-024) in Phase III clinical trials for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. Enobosam is an oral selective androgen receptor modulator

GTx is evaluating oral daily doses of Enobosarm 3 mg in patients with Stage III or IV non-small cell lung cancer in two pivotal Phase III clinical trials, POWER 1, and POWER 2, assessing the ability of the medication to prevent and treat muscle wasting.